ALDEVRON LICENSES THE MANUFACTURING OF A TYPE-V CRISPR NUCLEASE FROM INSCRIPTA
![Aldevron and Inscripta announcement](https://nationalstemcelltherapy.com/wp-content/uploads/2022/05/Aldevron_Insripta_Announcement-1024x576.jpg)
FARGO, N.D. , May 16, 2022 /PRNewswire/ —Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, along with Inscripta, a life science technology company dedicated to making CRISPR-based genome engineering accessible to any research lab, announced today the signing of an agreement that provides Aldevron […]